Список литературы

Поставить закладку

Давыдов М.И. Энциклопедия клинической онкологии. М.: РЛС-2004, 2004
Пачес А.И., Матякин Е.Г. Опухоли гортаноглотки. Опухоли головы и шеи: руководство/А.И. Пачес. 5-е изд., перераб и доп. М.: Практическая медицина, 2013. С. 182–85
Global Cancer Obserbvatory. Cancer Today. URL:http://gco.iarc.fr
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Cancer of the Hypopharynx. Version 3.2019
T M Jones, M De et al., Laryngeal cancer: United Kingdom National Multidisciplinary guidelines. The Journal of Laryngology & Otology (2016), 130 (Suppl. S2), S75–82
Fleming AJ, Jr., Smith SP, Jr., Paul CM, et al. Impact of [18F]-2- fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007;117:1173–79
Meulemans J, Delaere P, Vander Poorten V. Primary Treatment of T1-T2 Hypopharyngeal Cancer: Changing Paradigms. Adv Otorhinolaryngol. 2019;83:54-65
Tsou, Y.-A., Lin, M.-H., Hua, C.-H., et al. (2007). Survival outcome by early chemoradiation therapy salvage or early surgical salvage for the treatment of hypopharyngeal cancer. Otolaryngology-Head and Neck Surgery, 137(5), 711–716
Thomas LD, Basavaiah M, Mehanna N, Jones H, Paleri V. Open Conservation partial Laryngectomy for laryngeal cancer: a Systematic review of English language literature. Cancer Treat Rev 2012;38:203–11
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al.: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945–52
Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJ et al. Taxane cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013;31:2854–60
Huang, P.-W., Lin, C.-Y., Hsieh, C.-H., et al. (2018). A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. Biomedical Journal, 41(2), 129–136
Chen X, Xu J. Clinical analysis of cervical lymph node metastasis of hypopharyngeal carcinoma. 2011 Oct;25(19):891-4
Van der Laan HP, van de Water TA, van Herpt HE, et al. The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study // Acta Oncol. 2013. Vol. 52. P. 561-569
Ahn MJ, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. Oral Oncol 2016; 53:10–6
Noronha V, Joshi A, Patil VM, et al. Once-a-week versus once-every-3 weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol 2017: Jco2 017749457
Резолюция экспертного совета по вопросу о роли цетуксимаба в лечении пациентов с плоскоклеточным раком головы и шеи. Опухоли головы и шеи. 2019. № 8. С.71–3
Болотина Л. В., Владимирова Л. Ю., Деньгина Н. В., Новик А. В., Романов И. С. Практические рекомендации по лечению злокачественных опухолей головы и шеи // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 71–82
Jae-Sook Ahn, Sang-Hee Cho, Ok-Ki Kim et al. The Efficacy of an Induction Chemotherapy Combination with Docetaxel, Cisplatin, and 5-FU Followed by Concurrent Chemoradiotherapy in Advanced Head and Neck Cancer. Cancer Res Treat. 2007 Sep; 39(3): 93–98
Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27
Schöffski, P., Catimel, G., Planting et al. (1999). Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 10(1), 119–122
Gibson, M. K., Li, Y., Murphy, B., Hussain, M. H. A., DeConti, R. C., Ensley, J., & Forastiere, A. A. (2005). Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 23(15), 3562–3567
Jacobs, C., Lyman, G., Velez-García, E. et al (1992). A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology, 10(2), 257-263
Grau, J. josé, Caballero, M., et al (2009). Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Oto-Laryngologica, 129(11), 1294–1299
Catimel, G., Verweij, J., Mattijssen, V., et al (1994). Docetaxel (Taxotere®): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Annals of Oncology, 5(6), 533–537
Guardiola, E., Peyrade, F., Chaigneau, L. et al (2004). Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. European Journal of Cancer, 40(14), 2071–2076
Vermorken J.B., Trigo J., Hitt R. et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171–7
Martinez-Trufero J., Isla D., Adansa J.C. et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer 2010;102:1687–91
Ferris R., Blumenschein G., Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–67
Cohen E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study //The Lancet. – 2019. – Т. 393. – №. 10167. – С. 156-167
Clarke P., Radford K., Coffey M., Stewart M. Speech and swallow rehabilitation in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130(S2):S176–80
Сытов А. В., Лейдерман И. Н., Ломидзе С. В., Нехаев И. В., Хотеев А. Ж. Практические рекомендации по нутритивной поддержке онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2018 (том 8). С. 575–583
Zhao, S. G., Alexander, N. B., Djuric, Z., et al (2015). Maintaining physical activity during head and neck cancer treatment: Results of a pilot controlled trial. Head & Neck, 38(S1), E1086–E1096
Segal R., Zwaal C., Green E. et al. Exercise for people with cancer: a systematic review. Curr Oncol. 2017 Aug; 24(4): e290–e31
Samuel S.R., Maiya G.A., Fernandes D.J. et al. Effectiveness of exercise-based rehabilitation on functional capacity and quality of life in head and neck cancer patients receiving chemo-radiotherapy. Support Care Cancer 2019
Mustian K.M., Alfano C.M., Heckler C. et al: Comparison of pharmaceutical, psychological, and exercise treatments for cancer-related fatigue: a meta-analysis. JAMA Oncol 2017;3:961–8
Kinkead B., Schettler P.J., Larson E.R. et al. Massage therapy decreases cancer-related fatigue: results from a randomized early phase trial. Cancer 2018;124(3):546–54
Streckmann F., Zopf E.M., Lehmann H.C. et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289–304
Rick O., von Hehn U., Mikus E. et al. Magnetic field therapy in patients with cytostatics-induced polyneuropathy: a prospective randomized placebo–controlled phase-III study. Bioelectromagnetics 2016:38(2):85–94
Ross M., Fischer-Cartlidge E. Scalp cooling: a literature review of efficacy, safety, and tolerability for chemotherapy-induced alopecia. Clin J Oncol Nurs 2017;21(2):226–33
Avci P., Gupta G.K., Clark J. et al. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med 2013;46(2):144–51
Bensadoun R.J., Nair R.G. Low-level laser therapy in the management of mucositis and dermatitis induced by cancer therapy. Photomed Laser Surg 2015;33(10):487–91
Roopashri G. Radiotherapy and chemotherapy induced oral mucositis – prevention and current therapeutic modalities. IJDA 2010;2:174–9
Сопроводительная терапия в онкологии. Практическое руководство.Под ред. С.Ю. Мооркрафта, Д.Л.Ю. Ли, Д. Каннингэма. Пер. с англ. Под ред. А.Д. Каприна. М.: Гэотар, 2016. 432 c
Rosenthal D.I., Trotti A. Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 2009;19:29–34, Pauloski B.R. Rehabilitation of dysphagia following head and neck cancer. Phys Med Rehabil Clin N Am 2008;9:889‒928
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Cancer of the Hypopharynx. Version 1.2022
Болотина Л. В., Владимирова Л. Ю., Деньгина Н. В., Новик А. В., Романов И. С. Практические рекомендации по лечению злокачественных опухолей головы и шеи // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2022(том 12). С. 94–111.
Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13:145- 153.
Tahara M, Kiyota N, Yokota T, et al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Ann Oncol 2018;29:1004-1009. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29408977.
Harari PM, Harris J, Kies MS, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol 2014;32:2486-2495.